If You Invested in Psyched Wellness Ltd (PSYCF)

Psyched Wellness Ltd. (OTCQB: PSYCF) is a Canadian-based health supplements and life sciences company focused on the production and distribution of mushroom-derived consumer packaged goods. The company is repeatedly described in its disclosures as a health supplements company and a life sciences company specializing in products derived from the Amanita muscaria mushroom, using its proprietary extract known as AME-1.

According to multiple corporate updates, Psyched Wellness is dedicated to researching, producing and distributing mushroom-derived products and associated consumer packaged goods. The company’s stated objective is to create premium Amanita muscaria-derived and mushroom-derived products with the potential to become a North American brand in the emerging functional food category. Its activities include the development of Amanita muscaria-derived water-based extracts, teas and capsules that are being designed around three health objectives: promoting stress relief, supporting relaxation and assisting with restful sleeping.

Business focus and product development

Psyched Wellness describes itself as focused on the production and distribution of health and wellness products derived from the Amanita muscaria mushroom. A central element of its business is AME-1, which the company refers to as its proprietary extract of Amanita muscaria. Corporate communications state that Psyched Wellness is working to bring AME-1-based dietary supplements and related consumer products to market.

The company has disclosed the development and sale of several branded products built around AME-1. Its flagship product is Calm, which is associated with AME-1 and is produced in formats such as tinctures. Psyched Wellness has also announced Calmer, described as a new product offering that delivers twice the potency of Calm, and notes that it has enhanced the flavour profile of Calm in different bottle sizes while maintaining potency and consumer experience. In addition, the company has discussed the development of a dietary supplement shot, referred to in updates as a 4 oz shot and later as Santa, and has indicated that this format is being beta tested with target consumers.

Further product development efforts include Amanita muscaria gummies for sale in the United States, branded as Fly (Agaric). Psyched Wellness states that these gummies use AME-1 in their formulation and describes them as Amanita muscaria watermelon gummies intended for online and select retail availability. Across its communications, the company consistently notes that it is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules aligned with stress relief, relaxation and sleep-related objectives.

Scientific and regulatory work around AME-1

Psyched Wellness emphasizes scientific and regulatory work related to AME-1. The company has disclosed that it engaged a licensed contract research organization to complete a GAP analysis and path to market for its flagship product as a health supplement. It has also announced that it is conducting a Genotoxicity Study on AME-1, including tests such as the AMES test, in vitro TK-MLA assay and micronucleus assay, and has characterized progress as promising in its updates.

The company reports that a third-party laboratory conducted a six-month accelerated stability study on AME-1, with results indicating that AME-1 maintains muscimol content up to 18 months and shows no microbial growth under accelerated conditions. Based on this, Psyched Wellness has stated that Calm will carry an 18‑month shelf life. The company has also voluntarily submitted a New Dietary Ingredient Notification (NDIN) to the U.S. Food and Drug Administration for AME-1, describing the submission as including historical food use information and voluntary toxicology and safety studies of AME-1. In its own statements, Psyched Wellness indicates that it views itself as compliant with applicable U.S. dietary supplement law and emphasizes its focus on transparency and regulatory compliance as it brings additional AME-1 products to market.

Manufacturing, distribution and route-to-market

Corporate communications describe Psyched Wellness as focused on both direct-to-consumer online sales and brick-and-mortar retail distribution. The company notes that it uses a third-party manufacturing facility in the United States to produce AME-1 and Calm and has disclosed a supply chain disruption at that facility, stating that it would temporarily suspend online sales to prioritize inventory for retail partners and subscribers while working to secure additional contract manufacturers.

Psyched Wellness reports that it is growing its route-to-market partnerships across Canada and the United States and repeatedly invites interested distributors and retailers to contact the company regarding Calm and other products. It has highlighted relationships with specialty retailers, naming Erewhon, Central Markets, Good Earth Markets, Market of Choice and Harmons as retail partners that have signed on to sell Calm. The company also notes that it has engaged UNFI, described as a large wholesale distributor of health and specialty food across the United States and Canada, to support distribution for certain retail partnerships.

In its own statements, Psyched Wellness characterizes itself as focusing on working with a select group of specialty retailers that offer high-quality products and positions AME-1-based offerings as Amanita muscaria-derived products that are legal for human consumption in the United States. The company also references efforts to increase direct-to-consumer sales via its online store while adding key retailers in the wellness space.

Corporate profile and positioning

Across multiple news releases, Psyched Wellness describes itself as a Canadian-based health supplements company and a life sciences company focused on mushroom-derived products. It highlights its dedication to the distribution of mushroom-derived products and associated consumer packaged goods and to the research and production of consumer packaged goods derived from AME-1. The company’s stated objective is to create premium Amanita muscaria-derived products with potential in the functional food category, and it frequently references the emerging nature of this category in North America.

Psyched Wellness also discloses collaborations and advisory relationships, including work with Zerkalo LLC on brand development and new dietary supplement products using AME-1. It has mentioned a U.S. subsidiary, AME Wellness Inc., involved in pilot runs of new dietary supplement shots. The company notes that it has submitted a scaled-up extraction process patent application to the U.S. Patent and Trademark Office, with that application described as pending in the United States and Canada.

Risk considerations and forward-looking statements

In its cautionary statements, Psyched Wellness outlines risks and uncertainties associated with its business. These include the potential inability to continue as a going concern, possible governmental or regulatory actions affecting operations, competition in markets that include psychedelics and functional mushrooms, and risks related to the safety and purity of Amanita muscaria consumption and extracts, as well as the possibility that there may be no benefit from such consumption. The company emphasizes that forward-looking statements in its releases are based on assumptions about continued regulatory approval of its activities, the ability to develop mushroom-derived products and associated consumer packaged goods, and the continued growth of the company.

How Psyched Wellness stock is classified

On Stock Titan, Psyched Wellness Ltd. (PSYCF) is associated with the Pharmaceutical Preparation Manufacturing industry within the broader Manufacturing sector. At the same time, the company’s own descriptions emphasize its role as a health supplements and life sciences business centered on Amanita muscaria-derived consumer products, AME-1 and related formulations such as Calm, Calmer, Santa and Fly (Agaric) gummies.